Search
for
Sort by
Research 91–120 of 1000+
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- Tangled Causes, Targeted Solutions: A Comprehensive Review of Alopecia.
- Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options
- Integrated single-cell chromatin and transcriptomic analyses of peripheral immune cells in patients with alopecia areata
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- The Changing Landscape of Alopecia Areata: The Translational Landscape
- Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
- Novel therapies for alopecia areata: The era of rational drug development
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Pharmacological Treatment of Alopecia
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
- Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
- Research Progress on the Application of Stem Cells in Hair Regeneration
- Immune cell regulation of the hair cycle
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Direct reprogramming of human fibroblasts into hair-inducing dermal papilla cell-like cells by a single small molecule
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Janus kinase inhibitors for alopecia areata: A narrative review
- The JAK/STAT signaling pathway: from bench to clinic
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
- JAK inhibition decreases the autoimmune burden in Down syndrome
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- Phytochemicals for Hair Health Targeting Growth Signaling Molecules in Hair Follicular Stem Cells: A New Strategy for Hair Growth
- The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience